Red Light Therapy / Photobiomodulation (PBM)
Photobiomodulation (PBM) uses red (630–700 nm) and near-infrared (800–900 nm) light to stimulate mitochondrial cytochrome c oxidase, increasing ATP production in normal cells. In oncology, PBM is clinically validated for reducing oral mucositis (mouth sores) from chemotherapy/radiation — one of the most painful and treatment-limiting side effects. Additionally, at specific wavelengths combined with photosensitisers (like Methylene Blue), PBM becomes photodynamic therapy (PDT) which directly kills cancer cells.
Mechanism of Action
Red/NIR photons are absorbed by cytochrome c oxidase in mitochondria, increasing electron transport chain efficiency and ATP synthesis. In normal cells this is restorative. In PDT mode: tumour tissue is loaded with photosensitiser (Methylene Blue, 5-ALA, etc.), then illuminated with activating wavelength light — generating singlet oxygen and ROS directly within tumour cells with very high selectivity. PDT is FDA-approved for oesophageal, lung, and superficial skin cancers.
Cancer Types Studied
Protocols & Dosing
Oral Mucositis Prevention (Clinical Standard)
670 nm diode laser or LED panel applied intraorally for 5–10 J/cm² per session, daily during chemotherapy/radiation. Reduces mucositis severity by 60–80%. Standard of care in many cancer centres.
Home PBM Protocol
Consumer red/NIR panel (Joovv, Mito, or similar) — 660 nm + 850 nm, 20 min per area daily. Effective for wound healing, fatigue, neuropathy, and systemic anti-inflammatory effects.
Photodynamic Therapy (PDT) — Clinical
Photosensitiser administered (IV or topical) 24–72 h before procedure. Target tissue illuminated with specific wavelength light. FDA-approved for several cancer indications. Administered by oncologist.
NIH / PubMed Research
Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.
Cautions & Contraindications
- PDT causes severe photosensitivity for days–weeks after photosensitiser administration — sun avoidance critical
- Do not use red/NIR light directly over active cancerous tumours without photosensitiser protocol guidance — may theoretically stimulate bioenergetics
- Eye protection required — never look directly at red/NIR LEDs/lasers
- Home PBM devices vary greatly in quality — check irradiance (mW/cm²) specifications
- Mucositis prevention PBM should be performed by trained oncology team
Informational only. Not medical advice. Consult your oncologist before starting any alternative or integrative therapy.